US2008064640A1PendingUtilityA1

Mixture for transdermal delivery of low and high molecular weight compounds

71
Individually held — no corporate assignee on recordPriority: Jul 8, 1998Filed: Oct 31, 2007Published: Mar 13, 2008
Est. expiryJul 8, 2018(expired)· nominal 20-yr term from priority
Inventors:Frederick L. Jordan
A61K 9/0014A61K 8/922A61K 31/7052A61K 31/4152A61K 38/16A61K 47/44A61K 47/10A61K 31/135A61K 31/56A61K 31/195A61K 31/60A61Q 19/08A61K 31/404A61P 29/00A61K 31/5415A61K 31/47A61K 31/4985A61K 31/192A61K 38/08
71
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to the discovery of a transdermal delivery system that can deliver high molecular weight pharmaceuticals and cosmetic agents to skin cells. A novel transdermal delivery system with therapeutic and cosmetic application and methods of use of the foregoing is disclosed.

Claims

exact text as granted — not AI-modified
1 . A transdermal delivery system comprising: 
 an ethoxylated oil; and    a delivered agent mixed with said ethoxylated oil, wherein said ethoxylated oil contains between 10 and 19 ethoxylations/molecule.    
     
     
         2 . The transdermal delivery system of  claim 1 , wherein said ethoxylated oil contains 16 ethoxylations/molecule.  
     
     
         3 . The transdermal delivery system of  claim 1 , wherein said ethoxylated oil comprises an ethoxylated meadow foam oil.  
     
     
         4 . The transdermal delivery system of  claim 1 , wherein said delivered agent is less than 1,000 daltons.  
     
     
         5 . The transdermal delivery system of  claim 1 , wherein said delivered agent is 1,000 daltons or greater.  
     
     
         6 . The transdermal delivery system of  claim 1 , wherein said delivered agent is a steroid.  
     
     
         7 . The transdermal delivery system of  claim 1 , wherein said delivered agent is an antiviral compound.  
     
     
         8 . The transdermal delivery system of  claim 1 , wherein said delivered agent is a nucleic acid.  
     
     
         9 . The transdermal delivery system of  claim 1 , wherein said delivered agent is a peptide.  
     
     
         10 . The transdermal delivery system of  claim 1 , wherein said delivered agent is a non-steroidal anti inflammatory drug (NSAID).  
     
     
         11 . The transdermal delivery system of  claim 10 , wherein said non-steroidal anti inflammatory drug (NSAID) is selected from the group consisting of ibuprofen (2-(isobutylphenyl)-propionic acid); methotrexate (N-[4-(2, 4 diamino 6-pteridinyl-methyl]methylamino] benzoyl)-L-glutamic acid); aspirin (acetylsalicylic acid); salicylic acid; diphenhydramine (2-(diphenylmethoxy)-N,N-dimethylethylamine hydrochloride); naproxen (2-naphthaleneacetic acid, 6-methoxy-9-methyl-, sodium salt, (−)); phenylbutazone (4-butyl-1,2-diphenyl-3,5-pyrazolidinedione); sulindac-(2)-5-fluoro-2-methyl-1-[[p-(methylsulfinyl)phenyl]methylene-]-1H-indene-3-acetic acid; diflunisal (2′,4′, -difluoro-4-hydroxy-3-biphenylcarboxylic acid; piroxicam (4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-2-carboxamide 1,1-dioxide, an oxicam; indomethacin (1-(4-chlorobenzoyl)-5-methoxy-2-methyl-H-indole-3-acetic acid); meclofenamate sodium (N-(2,6-dichloro-m-tolyl) anthranilic acid, sodium salt, monohydrate); ketoprofen (2-(3-benzoylphenyl)-propionic acid; tolmetin sodium (sodium 1-methyl-5-(4-methylbenzoyl-1H-pyrrole-2-acetate dihydrate); 
 diclofenac sodium (2-[(2,6-dichlorophenyl)amino] benzeneatic acid, monosodium salt); hydroxychloroquine sulphate (2-{[4-[(7-chloro-4-quinolyl)amino] pentyl]ethylamino}ethanol sulfate (1:1); penicillamine (3-mercapto-D-valine); flurbiprofen ([1,1-biphenyl]-4-acetic acid, 2-fluoro-alphamethyl-, (+−)); cetodolac (1-8-diethyl-13,4,9, tetra hydropyrano-[3-4-13] indole-1-acetic acid; mefenamic acid (N-(2,3-xylyl)anthranilic acid; and diphenhydramine hydrochloride (2-diphenyl methoxy-N,N-di-methylethamine hydrochloride).    
     
     
         12 . The transdermal delivery system of  claim 1 , wherein said delivered agent is a collagen or fragment thereof.  
     
     
         13 . A method of transdermal delivery of a delivered agent comprising: 
 identifying a subject in need of transdermal delivery of a delivered agent; and    providing said subject a transdermal delivery system according to  claim 1 .    
     
     
         14 . The method of  claim 13 , wherein said transdermal delivery system comprises a delivered agent that is less than 1,000 daltons.  
     
     
         15 . The method of  claim 13 , wherein said transdermal delivery system comprises a delivered agent that is 1,000 daltons or greater.  
     
     
         16 . The method of  claim 13 , wherein said transdermal delivery system comprises a delivered agent that is a steroid.  
     
     
         17 . The method of  claim 13 , wherein said transdermal delivery system comprises a delivered agent that is an antiviral compound.  
     
     
         18 . The method of  claim 13 , wherein said transdermal delivery system comprises a delivered agent that is a nucleic acid.  
     
     
         19 . The method of  claim 13 , wherein said transdermal delivery system comprises a delivered agent that is a peptide.  
     
     
         20 . The method of  claim 19 , wherein said delivered agent is a non-steroidal anti inflammatory drug (NSAID).  
     
     
         21 . The method of  claim 20 , wherein said non-steroidal anti inflammatory drug (NSAID) is selected from the group consisting of ibuprofen (2-(isobutylphenyl)-propionic acid); methotrexate (N-[4-(2, 4 diamino 6-pteridinyl-methyl]methylamino] benzoyl)-L-glutamic acid); aspirin (acetylsalicylic acid); salicylic acid; diphenhydramine (2-(diphenylmethoxy)-N,N-dimethylethylamine hydrochloride); naproxen (2-naphthaleneacetic acid, 6-methoxy-9-methyl-, sodium salt, (−)); phenylbutazone (4-butyl-1,2-diphenyl-3,5-pyrazolidinedione); sulindac-(2)-5-fluoro-2-methyl-1-[[p-(methylsulfinyl)phenyl]methylene-]-1H-indene-3-acetic acid; diflunisal (2′,4′, -difluoro-4-hydroxy-3-biphenylcarboxylic acid; piroxicam (4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-2-carboxamide 1,1-dioxide, an oxicam; indomethacin (1-(4-chlorobenzoyl)-5-methoxy-2-methyl-H-indole-3-acetic acid); meclofenamate sodium (N-(2,6-dichloro-m-tolyl) anthranilic acid, sodium salt, monohydrate); ketoprofen (2-(3-benzoylphenyl)-propionic acid; tolmetin sodium (sodium 1-methyl-5-(4-methylbenzoyl-1H-pyrrole-2-acetate dihydrate); diclofenac sodium (2-[(2,6-dichlorophenyl)amino] benzeneatic acid, monosodium salt); 
 hydroxychloroquine sulphate (2-{[4-[(7-chloro-4-quinolyl)amino] pentyl]ethylamino}ethanol sulfate (1:1); penicillamine (3-mercapto-D-valine); flurbiprofen ([1,1-biphenyl]-4-acetic acid, 2-fluoro-alphamethyl-, (+−)); cetodolac (1-8-diethyl-13,4,9, tetra hydropyrano-[3-4-13] indole-1-acetic acid; mefenamic acid (N-(2,3-xylyl)anthranilic acid; and diphenhydramine hydrochloride (2-diphenyl methoxy-N,N-di-methylethamine hydrochloride).    
     
     
         22 . The method of  claim 13 , wherein said transdermal delivery system comprises a collagen or fragment thereof.  
     
     
         23 . The method of  claim 13 , further comprising; observing said subject for a response to said delivered agent, after providing said transdermal delivery system.  
     
     
         24 . A method of reducing pain or inflammation comprising: 
 identifying a subject in need of a reduction in pain or inflammation; and    providing said subject a transdermal delivery system according to  claim 10 .    
     
     
         25 . A method of reducing wrinkles in the skin comprising: 
 identifying a subject in need of a reduction in wrinkles in the skin; and    providing to said subject a transdermal delivery system according to  claim 1 .    
     
     
         26 . The method of  claim 25 , further comprising observing a reduction of wrinkles in the skin of said subject.  
     
     
         27 . The method of  claim 25 , wherein said transdermal delivery system comprises a collagen or fragment thereof.  
     
     
         28 . A method of restoring skin tone comprising: 
 (a) identifying a subject in need of a restoration of skin tone; and    (b) providing to said subject a transdermal delivery system according to  claim 12 .    
     
     
         29 . The method of  claim 28 , further comprising observing a restoration of skin tone in said subject.  
     
     
         30 . A method of increasing skin tightness comprising: 
 identifying a subject in need of skin tightness; and    providing to said subject a transdermal delivery system according to  claim 1 .    
     
     
         31 . The method of  claim 30 , further comprising observing an increase in skin tightness in said subject.  
     
     
         32 . A method of providing a peptide to a subject comprising: 
 (a) identifying a subject in need of said peptide; and    (b) providing said subject the transdermal delivery system of  claim 1 , wherein said delivered agent comprises a peptide that comprises the sequence LKEKK (SEQ. ID. No. 1).    
     
     
         33 . The method of  claim 32 , further comprising; 
 observing said subject for a response to said peptide, after providing said transdermal delivery system.

Join the waitlist — get patent alerts

Track US2008064640A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.